KRAS突变非小细胞肺癌内科治疗现状与展望
本文综述KRAS突变非小细胞肺癌的临床特征与内科治疗进展,指出该人群对系统性治疗反应差、预后不佳;法尼基转移酶抑制剂及下游通路抑制剂未获预期结果,KRAS曾被视为不可成药靶点;KRAS G12C抑制剂AMG510(sotorasib)与MRTX849(adagrasib)临床试验结果令人鼓舞,免疫检查点抑制剂研究亦有进展。
要点
- KRAS突变NSCLC患者对内科系统性治疗反应性差,预后不佳。
- 法尼基转移酶抑制剂及KRAS下游通路抑制剂研究均未取得预期结果。
- KRAS G12C抑制剂AMG510(sotorasib)与MRTX849(adagrasib)临床试验显示令人鼓舞的结果。
核心结论
- KRAS突变NSCLC对系统性内科治疗反应差、预后不佳,KRAS长期被视为不可成药靶点。
- 直接靶向KRAS的G12C抑制剂AMG510(sotorasib)与MRTX849(adagrasib)临床试验结果令人鼓舞。
- 近年免疫检查点抑制剂治疗KRAS突变NSCLC的研究取得一定进展。
研究设计与样本
- 本文为综述,系统介绍RAS基因基础认识、KRAS突变NSCLC临床特征及内科治疗,重点总结与展望KRAS靶向治疗研究进展。
主要发现
- KRAS是最早发现且突变频率较高的癌基因之一,KRAS蛋白作为分子开关与GTP结合后被激活。
- 法尼基转移酶抑制剂及KRAS信号通路下游蛋白抑制剂等靶向研究均未取得预期结果。
- KRAS G12C抑制剂AMG510(sotorasib)与MRTX849(adagrasib)在临床试验中显示令人鼓舞的结果。
- KRAS突变NSCLC患者对内科系统性治疗反应性差,预后不佳。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer remains the leading cause of cancer-related deaths in men and women worldwide, and 85% of these patients have non-small cell lung cancer. In recent years, the clinical use of targeted drug therapy and immune checkpoint inhibitors has dramatically changed the treatment landscape for advanced NSCLC. The mechanism and the value of targeted therapies have been a hot topic of research, as KRAS is one of the earliest discovered and most frequently mutated oncogenes, which is activated by binding to GTP and triggers a series of cascade reactions in cell proliferation and mitosis. The KRAS protein acts as a molecular switch and is activated by binding to GTP, triggering a series of cascade responses in cell proliferation and mitosis. Clinically, patients with KRAS mutated NSCLC have poor response to systemic medical therapy and poor prognosis. Since the first report of KRAS gene in 1982, research on KRAS targeted therapeutics has been slow, and previous studies such as farnesyltransferase inhibitors and downstream protein inhibitors of KRAS signaling pathway have not achieved the expected results, making KRAS long defined as a "non-druggable target". The deeper understanding of the crystal structure of KRAS has led to the discovery of potential therapeutic sites for KRAS and the development of several drugs directly targeting KRAS, especially KRAS G12C inhibitors such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have shown encouraging results in clinical trials. In recent years, studies on the therapeutic efficacy of immune checkpoint inhibitors for KRAS-mutated NSCLC have made some progress. In this review, we systematically introduce the basic understanding of RAS gene and clinical characteristics of KRAS mutated NSCLC patients, summarize the medical treatments for KRAS mutated NSCLC, including chemotherapy, anti-vascular drug therapy and tumor immunotherapy, and focus on the review and outlook of the research progress of KRAS targeted therapy. 近年来,靶向药物治疗和免疫检查点抑制剂的临床应用极大地改变了晚期非小细胞肺癌(NSCLC)的治疗格局。表皮生长因子受体和间变性淋巴瘤受体酪氨酸激酶等驱动基因改变NSCLC的TKI靶向治疗均已取得了良好临床疗效,而Kirsten大鼠肉瘤病毒基因同源物(KRAS)作为较早发现和突变频率较高的癌基因之一,其靶向药物治疗研究进展缓慢,法尼基转移酶抑制剂、KRAS信号通路下游蛋白抑制剂等靶向治疗研究均未取得预期结果,使得KRAS长期以来被定义为"不可成药的靶点"。KRAS蛋白作为分子开关,通过与三磷酸鸟苷结合而被激活,引发系列级联反应,在细胞增殖和有丝分裂中发挥作用。KRAS突变的NSCLC患者对内科系统性治疗反应性差,预后不佳。随着对KRAS晶体结构认识的不断深入,研究者发现了KRAS潜在的治疗位点,进而开发出了多个直接针对KRAS的靶向药物,尤其是KRAS G12C抑制剂,如AMG510(sotorasib)和MRTX849(adagrasib),其临床试验获得了令人鼓舞的结果。文章在系统介绍KRAS突变NSCLC患者临床特征及内科治疗方法的基础上,重点就KRAS靶向治疗的研究进展进行了总结和展望。.
引用
- Xu W, Zhuo XL, Liu L, et al. [Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2023. PMID: 36781231. doi:10.3760/cma.j.cn112152-20220310-00167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。